Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
BIOVIE INC. (BIVI) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/18/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/16/2023 10-K Annual Report for the period ended June 30, 2023
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/14/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/31/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/23/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/13/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "FIRST AMENDMENT TO BYLAWS OF BIOVIE INC. Adopted on March 12, 2023 The Bylaws of BioVie Inc. are amended as follows: Article III, Section 1 is amended in its entirety to read as follows: Section 1. Number and Term. The number of directors of the Corporation shall be fixed as the Board of Directors may from time-to-time designate, provided that the number of members of the Board shall not be less than three nor more than eleven . The number of authorized directors may be changed solely by action of the Board of Directors. No decrease in the number of directors shall have the effect of shortening the term of any incumbent director. Article III, Section 8, third paragraph is deleted, and the following two paragraphs are substituted: Regular meetings of the Board of Directors may be scheduled ..."
03/10/2023 SC 13D/A Acuitas Group Holdings, LLC reports a 72.1% stake in BIOVIE INC.
03/07/2023 SC 13D/A Acuitas Group Holdings, LLC reports a 87% stake in BIOVIE INC.
03/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/10/2023 10-Q Quarterly Report for the period ended December 31, 2022
12/23/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "50 West Liberty Street, Suite 1000, Reno, Nevada 89501-1950 Telephone: 775.323.1980 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169 Telephone: 702.387.6073 BioVie Inc. 680 West Nye Lane, Suite201 Carson City, Nevada 489703"
12/23/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "50 West Liberty Street, Suite 1000, Reno, Nevada 89501-1950 Telephone: 775.323.1980 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169 Telephone: 702.387.6073 BioVie Inc. 680 West Nye Lane, Suite 201 Carson City, Nevada 489703"
12/14/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
12/12/2022 RW Form RW - Registration Withdrawal Request:
12/07/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
12/05/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/10/2022 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
11/10/2022 8-K Quarterly results
11/04/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/04/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioVie Issues Letter to Shareholders ● Positive preliminary data from investigator-sponsored Phase 2 Alzheimer’ s trial show high proportion of responders and level of cognitive improvements seen for NE3107 confirm NE3107’ s status as one of the most promising candidates in the Alzheimer’ s space ● Potentially pivotal Phase 3 trial for NE3107 in Alzheimer’ s has enrolled over half the targeted patients and is on track to readout mid-2023 ● Early and preliminary evidence in Phase 2 Parkinson’ s trial for NE3107 may suggest findings consistent with that previously seen in non-human primates and should readout before year-end 2022 ● Three significant data readouts expected over the next 12 months Carson City, NV, October 4, 2022 – BioVie Inc., a clinical-stage company..."
09/30/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
09/30/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
09/27/2022 10-K Annual Report for the period ended June 30, 2022
09/07/2022 8-K/A Investor presentation
Docs: "BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’ s Disease BioVie Provides Updates on Other Clinical Programs"
09/07/2022 8-K Investor presentation
Docs: "BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’ s Disease BioVie Provides Updates on Other Clinical Programs"
08/31/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Sales Agreement",
"50 West Liberty Street, Suite 1000, Reno, Nevada 89501-1950 Telephone: 775.323.1980 3960 Howard Hughes Parkway, Suite 500, Las Vegas, Nevada 89169 Telephone: 702.387.6073 BioVie Inc. 680 West Nye Lane, Suite201 Carson City, Nevada 489703"
08/31/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/16/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/25/2022 D Form D - Notice of Exempt Offering of Securities:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy